Mehta Vimal 4
4 · BioXcel Therapeutics, Inc. · Filed Apr 1, 2025
Insider Transaction Report
Form 4
Mehta Vimal
DirectorCEO and President
Transactions
- Award
Stock Option (right to buy)
2024-07-22+6,250→ 6,250 totalExercise: $1.20Exp: 2034-07-22→ Common Stock (6,250 underlying)
Footnotes (2)
- [F1]The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock.
- [F2]The Reporting Person was granted an option to purchase 6,250 shares of common stock, which vests as to 50% on each of the first and second anniversaries of the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.